The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Updates from Gesine Paul-Visse's Lab

Blåklädda kirurger i en operationssal
Photo from stem cell transplantation at Skåne University Hospital. Source: Skåne University Hospital.

There is a lot going on around the clinical WCMM researcher Gesine Paul-Visse right now! Both press releases and interviews is coming out of her lab. We could also catch a glimpse of her when Swedish Television made a short interview with the very first patient enrolled in the STEM-PD clinical trial and receiving stem cell treatment for his Parkinson’s disease.

There has been several press releases, publications and interesting results coming from the lab of WCMM clinical researcher Gesine Paul-Visse lately. Both regarding updates on the STEM-PD clinical trial that we have written about earlier and a new publication with results showing that cell-specific biomarkers in the blood reflect what happens in the brain during stroke. 

The STEM-PD clinical trial

After a positive initial safety evaluation in Parkinson's therapy, the pioneering STEM-PD clinical trial has advanced to higher dose testing. STEM-PD is a first-in-human clinical trial testing a new investigational therapy for Parkinson’s disease aimed at replacing the dopamine cells lost to the disease with healthy ones derived from stem cells.

The first patient in the the trial was transplanted at Skåne University Hospital, Lund, Sweden, in February 2023, and the STEM-PD team now announces to have completed dosing of the first four patients with the initial lower dose of cells (3.5 million cells per putamen/7 million in total). Based on the safety data, the study team has now proceeded as planned and initiated dosing of the next four patients with a higher dose of cells (7 million cells per putamen/14 million in total). 

The first patient in the higher dose cohort has now been transplanted and the remaining 3 patients will be grafted during 2024 and followed for 36 months within this trial. Swedish television har published an interview with Thomas Matsson, who is the first patient being transplanted with stem cells in the STEM-PD clinical trial. 

Blood biomarkers reflect what happens in the brain during stroke

By analysing small microvesicles that cells release to communicate with their surroundings in the blood, researchers at Lund University map what happens in the brains of stroke patients. The study published in the scientific journal Stroke expands our understanding of stroke and opens doors to new treatment strategies.
Read more about the results from this study:


What is STEM-PD?

STEM-PD is a clinical trial run by clinical and preclinical research teams in Sweden and the UK. The goal of the trial is to develop a safe and efficacious stem cell-based treatment for Parkinson’s disease.

The trial involves transplantation of stem cell-derived dopamine STEM-PD cells into the brains of Parkinson’s disease patients. The stem cell product to be transplanted in this trial is named “STEM-PD”. The cells are designed to form new functional dopamine neurons in the brain of the patient after transplantation, with the aim of replacing those neurons which have been lost during the course of the disease.

This clinical trial is an investigator-lead clinical trial sponsored by Skåne University Hospital in Lund and registered as EudraCT 2021-001366-38. The development of the product and the clinical trial has been funded by national and EU funding agencies as well as by the pharmaceutical company Novo Nordisk.

Read more